gdc-0973 and Central-Nervous-System-Neoplasms

gdc-0973 has been researched along with Central-Nervous-System-Neoplasms* in 1 studies

Trials

1 trial(s) available for gdc-0973 and Central-Nervous-System-Neoplasms

Article	Year
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. The Lancet. Oncology, 2022, Volume: 23, Issue:9 Targeted therapy and immunotherapy have shown intracranial activity in melanoma with CNS metastases, but there remains an unmet need, particularly for patients with symptomatic CNS metastases. We aimed to evaluate atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib in patients with melanoma with CNS metastases.. TRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAF. Between Dec 13, 2018, and Dec 7, 2020, 65 patients were enrolled in the BRAF. Adding atezolizumab to vemurafenib plus cobimetinib provided promising intracranial activity in patients with BRAF. F Hoffmann-La Roche. Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Central Nervous System Neoplasms; Humans; Melanoma; Mutation; Neoplasms, Second Primary; Piperidines; Proto-Oncogene Proteins B-raf; Vemurafenib	2022

Article

Year

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.

The Lancet. Oncology, 2022, Volume: 23, Issue:9

Targeted therapy and immunotherapy have shown intracranial activity in melanoma with CNS metastases, but there remains an unmet need, particularly for patients with symptomatic CNS metastases. We aimed to evaluate atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib in patients with melanoma with CNS metastases.. TRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAF. Between Dec 13, 2018, and Dec 7, 2020, 65 patients were enrolled in the BRAF. Adding atezolizumab to vemurafenib plus cobimetinib provided promising intracranial activity in patients with BRAF. F Hoffmann-La Roche.

Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Central Nervous System Neoplasms; Humans; Melanoma; Mutation; Neoplasms, Second Primary; Piperidines; Proto-Oncogene Proteins B-raf; Vemurafenib

2022